Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | DPP3 | Q9NY33 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.49 |
| ▸ | ITGAL | P20701 | 1/20 | 0.49 |
| ▸ | F13A1 | P00488 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30511908 | 0.97 | GHSR (0.56) | GHSRBCHEDPP3CYP2C19F13A1 | |
| SCHEMBL18933365 | 0.91 | DPP3 (0.53) | GHSRBCHEDPP3F13A1TGM2 | |
| SCHEMBL14906600 | 0.91 | DPP3 (0.49) | GHSRBCHEDPP3 | |
| SCHEMBL14906478 | 0.91 | DPP3 (0.49) | GHSRBCHEDPP3 | |
| SCHEMBL29812309 | 0.90 | DPP3 (0.64) | GHSRDPP3ITGB2ICAM1ITGAL | |
| SCHEMBL14903326 | 0.89 | DPP3 (0.49) | GHSRDPP3TACR1 | |
| SCHEMBL2193319 | 0.87 | GHSR (0.52) | GHSRBCHEDPP3F13A1TGM2 | |
| SCHEMBL11857684 | 0.86 | TRHR (0.54) | BCHEDPP3CYP2C19ITGB2ICAM1 | |
| SCHEMBL30051356 | 0.84 | ITGB2 (0.56) | GHSRBCHEDPP3ITGB2ICAM1 | |
| SCHEMBL29878760 | 0.84 | ACE (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-119841827-A | Purine compounds and application thereof | 中国科学院上海药物研究所 | 2025-04-18 | — | — | CN | disclosed |
| CN-118894917-B | Feta protein zymolyte, preparation method and application | 澳优乳业（中国）有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | GHSR 429/4885BCHE 353/4885DPP3 25/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | GHSR 679/4885BCHE 231/4885DPP3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.